Inetetamab triggers cardiotoxicity through its interaction with apoptosis, oxidative stress and autophagy pathways
Abstract Inetetamab, a trastuzumab biosimilar, has obtained approval for the treatment of HER2-positive advanced metastatic breast cancer. Despite studies indicating its cardiotoxic properties, the intricate mechanisms underlying its toxicity remain elusive. In the present study, we demonstrated in...
Saved in:
| Main Authors: | Weiqun Wang, Hongliang Zhang, Yikun Qu, Yue Li, Peng Peng, Chengbo Lu, Xinyue Zhao, Ziteng Cai, Chaonan Peng, Xiaoli Guo, Yuxin Guo, Jie Li, Xuebin Li, Linlin Jia, Guangyuan Yang |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Nature Portfolio
2025-07-01
|
| Series: | Scientific Reports |
| Subjects: | |
| Online Access: | https://doi.org/10.1038/s41598-025-02125-5 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Cardiotoxicity of Anticancer Drugs
by: I. Maiborodin, et al.
Published: (2025-02-01) -
MicroRNAs in anthracycline cardiotoxicity: biomarkers, mechanisms, and therapeutic advances
by: Hongyun Mao, et al.
Published: (2025-08-01) -
The function of PCSK9 in doxorubicin-induced cardiotoxicity and its underlying mechanism
by: Shuai Shi, et al.
Published: (2025-07-01) -
Сonsensus statement of Russian experts on the prevention, diagnosis and treatment of cardiotoxicity of anticancer therapy
by: Yu. A. Vasyuk, et al.
Published: (2021-10-01) -
Natural strategies of preventing anthracycline-induced cardiotoxicity – a review
by: Anca STOICA, et al.
Published: (2022-12-01)